120 results about "Sphingomyelin metabolism" patented technology

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.

The present invention discloses a method to prepare specific liposomal formulations for the pulmonary application of therapeutic substances. The liposomal components, DPPC and cholesterol at a molar ratio of 7:3 and 7:4, respectively, are combined with the non-toxic excipients, sphingomyelin, dimyristoylphophatidylcholine and / or polyethylene glycol, to prepare liposomes that are stabile during nebulization with commercially available nebulizers and exhibit sustained release kinetics of encapsulated drug substances.

The present invention provides a method for treating individuals affected with the acid sphingomyelinase-deficient forms of Niemann-Pick disease (i.e., Type A or Type B Niemann-Pick) by administering small molecules as specific molecular “chaperones” for the deficient acid sphingomyelinase (ASM) enzyme associated with the disease. The molecules are ceramide, sphingomyelin, or phosphonucleotide analogues.

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

A stable polymer micella carrier system for medicines is composed of an amphipathic block copolymer including diblock copolymer and triblock copolymer and a phosphatide chosen from glyceryl phosphatide, sphingomyelin, and their derivatives.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The invention relates to a targeted lipidosome drug-loading system containing aptamers and a preparation method of the system. The targeted lipidosome drug-loading system containing the aptamers comprises the aptamers, an antitumor drug and nano-liposomes prepared from sphingomyelin, wherein the antitumor drug is wrapped with the nano-liposomes and the aptamers are connected onto the nano-liposomes through chemical bonds for specifically identifying tumor cells. The nano-liposomes are prepared from sphingomyelin and are connected with an appropriate quantity of the aptamers after the antitumor drug is wrapped with the nano-liposomes, sphingomyelin contains more amido bonds and can resist chemical and biological degradation better, protect stability of a lipidosome structure and increase the drug accumulation content of the tumor cells, and accordingly, the antitumor effect is improved.

The invention provides infant formula milk powder for improving health of intestinal tracts, which is prepared with raw milk as a main raw material with addition of whey protein powder being rich in MFGM and other materials. By means of the novel whey protein powder being rich in MFGM as the raw material, contents of bio-active substances having special functional components, such as MFGM protein, lactoferrin, phospholipid, gangliosides, sphingomyelin, sialic acid and the like, are increased by regulation of the formula, so that the milk powder can promote colonization of probiotics in intestinal flora of infants and improves the content of immune factors in intestinal tracts and reduces intestinal disease incidence. The formula is suitable for researching on formula milk powder for infants and follow-up infants.

An object of the present invention is to provide a protein useful as a sphingomyelin detecting probe, which specifically recognizes sphingomyelin and has low cytotoxicity. The present invention provides a protein which has an amino acid sequence having, as the amino acid sequence from the 1st to the 48th amino acid, the amino acid sequence from the 1st to the 48th amino acid in Lysenin 1, and as the amino acid sequence from the 49th to the 298th amino acid, the amino acid sequence from the 51st to the 300th amino acid in Lysenin 3; and a protein which is obtained by deleting N terminal and / or C terminal from earthworm toxins Lysenin 1 or 3, and which specifically recognizes sphingomyelin.

The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and / or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.

This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C8-GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C6-SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C1-6alkyl-phosphate group; R2 is independently C3-9alkyl, and is independently unsubstituted or substituted; R3 is independently C7-19alkyl, and is independently unsubstituted or substituted; R4 is independently —H, —OH, or —O—C1-4alkyl; RN is independently —H or C1-4alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R5 is —H; if the bond marked with an alpha (α) is a single bond, then R5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.

The invention discloses an Argatroban liposome injection and a preparation method thereof. The Argatroban liposome injection with excellent quality is prepared by selecting Argatroban, sphingomyelin, octadecylamine, and tween 80 according to specific proportion. Compared with preparations in the prior art, the injection disclosed herein has improved stability and bioavailability, improved qualityof the preparation products, reduced toxic and side effect, stable drug release, and remarkable curative effect.

The present invention is in the field of prevention and treatment of atherosclerosis and atherosclerosis-related clinical conditions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside lyso-sphingomyelin and / or sphingomyelin for prevention and treatment of inflammatory processes associated with atherosclerosis, psoriasis, colitis or auto-immune diseases in a subject.

The invention relates to a method for assessing the risk of a cardiovascular disease and / or for diagnosing dyslipidemia in a patient, said method comprising: a) isolating in a blood sample obtained from said patient the high density lipoprotein (HDL) fraction or a subfraction thereof; and b) measuring in said HDL fraction or subfraction thereof the concentration of one or more biomarkers selected from the group consisting of Sphingosine-1-Phosphate (S1P), sphingomyelin (SM) and Apolipoprotein A-I (apoA-1).

The invention discloses a multi-effect eye cream and a preparation method thereof, aims to provide an eye cream that can effectively eliminate eyes redness, alleviate dry eyes and fade dark eye circles; the eye cream is prepared from the components of tocopheryl acetate, trehalose, macadamia ternifolia seed oil, moringa pterygosperma seed extract, yeast ferment extract, chondrus crispus extract, centella asiatica extract, ruscus aculeatus root extract, hedera helix extract, escin, panthenol, lecithin, caffeine, phospholipid, sphingomyelin, sodium hyaluronate, dipotassium glycyrrhizinate, tripeptide-1 and the like; and belongs to the field of cosmetics.

The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.

The present invention relates to a nutritional composition, in particular directed to toddlers and / or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises sphingomyelin, sialic acid, choline, essential fatty acids and taurine.

A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine. Also provided are kits useful for the methods of the invention.

A medicine 'Sphingomyelin isopropyl-phenol fatty emulsion' with target function to central nerve is prepared from isopropyl-phenol, sphingomyelin, lecithin, refined soybean oil or other oils, VE and glycerin. Its preparing process is also disclosed.

The invention discloses a method for screening specific serum metabolism markers for triple-negative breast cancer. The method includes respectively carrying out metabonomics analysis on serum samples of experimental groups A and control groups B by the aid of LC / MS (liquid chromatography / mass spectrometry) instruments; carrying out model discriminant analysis on response intensity data of peaks of substances in the samples; respectively carrying out PCA (principal component analysis) on the experimental groups A and the control groups B; building PLS-DA (partial least square- discriminant analysis) and OPLS-DA (orthogonal partial least square-discriminant analysis) models on the basis so as to obtain difference expression metabolites; screening and identifying the biological markers related to breast cancer carcinogenesis and metastasis. The biological markers include hemolytic lecithin, sphingomyelin and small-molecule amino acid. The method has the advantages that results obtained by the aid of the method have an important significance on illustrating change rules of contents of characteristic metabolites in the serum of patients who suffer from the triple-negative breast cancer and illustrating effects of the metabolites in tumor formation and development procedures; effective breast cancer early diagnosis target sites can be acquired by the aid of the method, and data bases can be provided for establishing specific cancer diagnosis models.

The present disclosure provides a liposomal system comprising an aqueous medium having dispersed therein liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the aqueous medium being in iso-osmotic equilibrium with said intraliposomal aqueous compartment, the liposomes having a membrane comprising a liposome forming lipids, at least one of which being sphingomyelin (SPM), the liposomal system having increased stability as compared to the same liposomes free of SPM, and in one embodiment being stable during long-term storage, said stability being characterized in that no more than 30% of the at least one active agent is present in the aqueous medium after said storage. Further provided by the present disclosure are a method for storage of liposomes making use of the liposomal system; use of the liposomal system for the treatment of a medical condition or for the diagnostic of a medical condition; a pharmaceutical or diagnostic composition comprising the liposomal system, and a method of treating or diagnosing of a medical condition comprising administering to a subject an amount of the liposomal system.

This invention provides compositions, methods and systems to modulate the lipid content and membrane characteristics of cells and virions. Growth of host cells on media containing particular amounts, classes and / or combinations of lipid supplements can influence the lipid content of the cell and viruses grown on the cell. Lipids, such as cholesterol esters, sphingomyelin, glycolipids, containing C16:0, C18:0, C18: 1n9 and / or C18:2n6 fatty acids, can influence cell permissivity for virus infection, virus yield, virus immunogenicity and / or membrane phase transition temperatures.

The invention provides infant formula milk powder rich in milk fat globule membrane protein and phospholipid. By adding alpha-lactalbumin, milk fat globule membrane and a physiological activator, suchas bifidobacterium animalis Bb-12, milk fat globule membrane lipids and protein, N-acetylneuraminic acid (sialic acid), SN-2 structure lipid, human milk oligosaccharides (HMOs) and human milk oligose(HMO). By simultaneously adjusting the using amount ratio of all the components, especially sphingomyelin, gangliosides, the milk fat globule membrane protein, the human milk oligosaccharides, the human milk oligose, adiponectin and lysozyme, and the proportion between mucin, xanthine oxidoreductase, mucin 15, CD 36, butyrophilin, adipose differentiation-related protein and fatty acid binding proteins, the content of the active ingredients in the milk powder is closer to the content of active ingredients in human milk, the constitution of the infant formula milk powder is optimized, and the formula milk powder obtained by using the method is closer to the human milk.

Disclosed is an agent for facilitating the development of the brain in an infant, which comprises an effective amount of a milk-derived phospholipid or a sphingomyelin. Also disclosed is a food composition for improving the nervimotion and / or the learning function in an infant, which comprises the agent. For direct intake, the agent preferably comprises at least 0.027 wt% of a milk-derived phospholipid or at least 0.005 wt% of a sphingomyelin.

The invention discloses a kit for distinguishing colorectal adenomas from colorectal cancer. The kit for distinguishing or assisting in distinguishing the colorectal adenomas from the colorectal cancer comprises a device for detecting phospholipids content and a contrast card established by the phospholipids content, wherein phospholipids are sphingosylphosphorylcholine (SPC), 16:0 sphingomyelin (SM), 18:0SM, 14:0 lysophosphatidylcholine (LPC), 16:0LPC, 18:0LPC, 20:0LPC and 22:0LPC. Saturated LPC, SPC and SM are taken as markers, and a molecular model for distinguishing the colorectal adenomas from the colorectal cancer is established, and has colorectal cancer distinguishing sensitivity of 90 percent and colorectal cancer distinguishing specificity of 93 percent.

Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.